Our results indicate that GSK3326595, a PRMT5-specific inhibitor, is a potentially effective drug for reducing CRC immune evasion by blocking ALKBH5 methylation and ALKBH5–CD276 interaction. This evidence concerns the gene PRMT5 and colorectal carcinoma.